Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years

Area of Science:

• Uro-oncology
• Cancer research
• Clinical trial design

Background:

• Invasive, non-metastatic bladder cancer has a suboptimal cure rate of approximately 50%.
• Systemic spread is the predominant pattern of relapse, suggesting the presence of occult metastases at diagnosis.
• Current therapeutic strategies, including neoadjuvant chemotherapy and advanced surgical/radiological techniques, have not significantly improved cure rates.

Purpose of the Study:

• To review the historical therapeutic strategies for invasive bladder cancer.
• To identify limitations in current treatment paradigms and research methodologies.
• To propose a framework for future research focusing on molecular and immunological targets.

Main Methods:

• Review of historical therapeutic strategies and clinical trial outcomes in invasive bladder cancer.
• Analysis of relapse patterns and the impact of systemic spread.
• Discussion of the potential of molecular prognostication and immune responsiveness.

Main Results:

• Despite decades of research, cure rates for invasive bladder cancer have not substantially improved.
• Many neoadjuvant chemotherapy trials have failed due to testing ineffective metastatic regimens.
• Genetic analysis has had limited impact on predicting or improving outcomes.

Conclusions:

• Future progress in invasive bladder cancer treatment hinges on leveraging molecular prognostication and understanding immune responsiveness.
• Adherence to logical investigative rules is crucial for advancing clinical practice.
• Five guiding principles are proposed for future study development in bladder cancer research.